The characteristics of the included studies were summarized in Table 1, which encompassed cohort time periods, diagnosis of DM and exposure to metformin, gender, age, BMI, HbA1c level, pretreatment CEA, response on tumor regression grade (TRG), and the proportion of pCR. The gene discussed is CEACAM5; the disease is neoplasm.